諾輝健康(6606.HK)常衞清®618銷量突破5000份 50歲以上用户是主力
6月21日， 諾輝健康(6606.HK)發佈618直營電商戰績：2021年6月1日0時至6月18日24時，根據京東商智和生意參謀統計數據，常衞清®累計銷售量突破5000份。
據京東健康618戰報，諾輝健康京東旗艦店奪得618期間京東基因檢測類目行業銷售額、單品銷售額雙冠軍及618當日消費醫療榜冠軍。
“防癌科普持續成為快手、抖音等主流平台的熱詞。從此次618期間常衞清銷售量的增長，我們可以清楚的看到居家防癌早篩得到了一線城市高風險人羣的迅速認同。”諾輝健康執行董事兼CEO朱葉青表示，“基因檢測類的健康消費今年618在電商平台嶄露頭角，雖然規模尚小，但增長迅速，有望成為健康消費升級的新動力。”
6月15日起，諾輝健康首次聯合快手健康和小荷健康，發起#腸道健康 防癌早篩#的話題徵集，發動超過近200位入駐平台的醫生與科普達人宣傳結直腸癌防治常識，提高結直腸癌高風險人羣的健康風險意識，根據臨牀指南科學規範早篩手段。其中，“#防癌早篩在快手”的話題，上線一週累計收穫4167.7萬次播放量。
2020年11月9日，諾輝健康旗下常衞清®獲批國家藥品監督管理局三類醫療器械註冊證，拿下了中國首個也是目前唯一的癌症早篩證。隨後，諾輝健康在京東健康和天貓商城雙店齊開。根據電商累計訂單數據分析，常衞清®用户呈以下特點：
● 北京、廣東、上海、浙江、江蘇、山東用户購買居前列，佔訂單總數超6成；
● 購買用户的主力年齡區間為26-45歲，佔總購買人數近8成；
● 受檢用户的主力年齡區間為40-59歲，佔總受測人數超7成；
● 受檢者中男性用户40-49歲最多，女性用户50-59歲最多，男性比女性用户更早關注篩查，男女用户比例基本保持1.4：1；
● 受檢者隨訪調查反饋，9成以上的用户有體檢的習慣；
● 受檢者的陽性率為9.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
